PURE QUININE RED POWDER 2.OZ

  • Listing id
    0ccyigcy
  • Categories
  • Asking price

    Asking $11.95 USD per item

  • Quantity

    20 items (New)

  • Tax
    Not applicable
  • Shipping & Handling

    Shipping to the United States only

    Buyer pays shippping cost $4.95 USD

  • Payment Terms

    Payment in advance only

    Seller accepts Money order / Cashiers check, PayPal, PayPal

  • Posted
    1 month ago
carlos49
Barb, OH
Member since January 4, 2022
(201) 648-7779
Please only contact the seller if you are interested in buying or bartering for this item. Spam and fraud will not be tolerated.
2.oz Pure Quina- Quinine Cinchona Red Quina Powder
from Honduras

The powder was made form the bark collected from wild Red Cinchona or Quina Trees in La Moskitia , Honduras.
Malaria Journal volume 10, Article number: 144 (2011) Cite this article

Article metrics

124k Accesses 220 Citations 301 Altmetric Metricsdetails
Abstract

Quinine remains an important anti-malarial drug almost 400 years after its effectiveness was first documented. However, its continued use is challenged by its poor tolerability, poor compliance with complex dosing regimens, and the availability of more efficacious anti-malarial drugs. This article reviews the historical role of quinine, considers its current usage and provides insight into its appropriate future use in the treatment of malaria. In light of recent research findings intravenous artesunate should be the first-line drug for severe malaria, with quinine as an alternative.

The role of rectal quinine as pre-referral treatment for severe malaria has not been fully explored, but it remains a promising intervention. In pregnancy, quinine continues to play a critical role in the management of malaria, especially in the first trimester, and it will remain a mainstay of treatment until safer alternatives become available. For uncomplicated malaria, artemisinin-based combination therapy (ACT) offers a better option than quinine though the difficulty of maintaining a steady supply of ACT in resource-limited settings renders the rapid withdrawal of quinine for uncomplicated malaria cases risky.

The best approach would be to identify solutions to ACT stock-outs, maintain quinine in case of ACT stock-outs, and evaluate strategies for improving quinine treatment outcomes by combining it with antibiotics. In HIV and TB infected populations, concerns about potential interactions between quinine and antiretroviral and anti-tuberculosis drugs exist, and these will need further research and pharmacovigilance.